Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease

Current Opinion in Immunology

Volumn 40, Issue , 2016, Pages 51-61

  Corti, Davide ^a   Kearns, Jeffrey D ^b  

^a Humabs BioMed SA ^*  (Switzerland)

^b MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT OLIGOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; OLIGOCLONAL BAND; RECOMBINANT PROTEIN;

BACTERIAL INFECTION; CANCER IMMUNOTHERAPY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOLOGY; REVIEW; TREATMENT RESPONSE; VIRUS INFECTION; ANIMAL; ANTIGENIC MODULATION; ANTIGENIC VARIATION; IMMUNOLOGY; IMMUNOTHERAPY; INFECTION; NEOPLASMS; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENIC MODULATION; ANTIGENIC VARIATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; INFECTION; NEOPLASMS; OLIGOCLONAL BANDS; RECOMBINANT PROTEINS;

EID: 84961122598     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.03.001     Document Type: Review

References (115)

1. Wang X.-Z., Coljee V.W., Maynard J.A. Back to the future: recombinant polyclonal antibody therapeutics. Curr Opin Chem Eng 2013, 2:405-415.
2. Gupta R.K., Glassy M.C. Oligoclonal and polyclonal antibody preparations. Handbook of Therapeutic Antibodies 2014, 1289-1308. Wiley-VCH Verlag GmbH & Co. KGaA. S. Dübel, J.M. Reichert (Eds.).
3. Carvalho S., Levi-Schaffer F., Sela M., Yarden Y. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review X. Br J Pharmacol 2016, in press.
4. Mahoney K.M., Rennert P.D., Freeman G.J. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015, 14:561-584.
5. Smilek D.E., Ehlers M.R., Nepom G.T. Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech 2014, 7:503-513.
6. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat Rev Cancer 2012, 12:278-287.
7. Weiner G.J. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 2015, 15:361-370.
8. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 2009, 1:443-452.
9. Chon J.H., Zarbis-Papastoitsis G. Advances in the production and downstream processing of antibodies. New Biotechnol 2011, 28:458-463.
10. Reichert J.M. Antibodies to watch in 2015. MAbs 2015, 7:1-8.
11. Henricks L.M., Schellens J.H.M., Huitema A.D.R., Beijnen J.H. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat Rev 2015, 41:859-867.
12. Demarest S.J., Hariharan K., Dong J. Emerging antibody combinations in oncology. MAbs 2011, 3:338-351.
13. Swain S.M., Kim S.-B., Cortés J., Ro J., Semiglazov V., Campone M., Ciruelos E., Ferrero J.-M., Schneeweiss A., Knott A., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013, 14:461-471.
14. Swain S.M., Baselga J., Kim S.-B., Ro J., Semiglazov V., Campone M., Ciruelos E., Ferrero J.-M., Schneeweiss A., Heeson S., et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med 2015, 372:724-734.
15. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., Schadendorf D., Dummer R., Smylie M., Rutkowski P., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015, 373:23-34.
16. Gianni L., Romieu G.H., Lichinitser M., Serrano S.V., Mansutti M., Pivot X., Mariani P., Andre F., Chan A., Lipatov O., et al. AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer. J Clin Oncol 2013, 31:1719-1725.
17. Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., Marshall J., Cohn A., McCollum D., Stella P., et al. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. J Clin Oncol 2009, 27:672-680.
18. Ocean A.J., Polite B., Christos P., Horvath L., Hamilton A., Matulich D., Chen H.X., Sparano J.A., Kindler H.L. Cetuximab is associated with excessive toxicity when combined with bevacizumab plus mFOLFOX6 in metastatic colorectal carcinoma. Clin Colorectal Cancer 2010, 9:290-296.
19. Dotan E., Meropol N.J., Burtness B., Denlinger C.S., Lee J., Mintzer D., Zhu F., Ruth K., Tuttle H., Sylvester J., et al. A Phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase Extramural Research Study. J Gastrointest Cancer 2012, 43:562-569.
20. Van Cutsem E., Eng C., Nowara E., Wieboda-Sadlej A., Tebbutt N.C., Mitchell E., Davidenko I., Stephenson J., Elez E., Prenen H., et al. Randomized Phase Ib/II Trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res 2014, 20:4240-4250.
21. Melero I., Berman D.M., Aznar M.A., Korman A.J., Gracia J.L.P., Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015, 15:457-472.
22. Yonezawa A., Dutt S., Chester C., Kim J., Kohrt H.E. Boosting cancer immunotherapy with anti-CD137 antibody therapy. Clin Cancer Res 2015, 21:3113-3120.
23. Kearns J.D., Bukhalid R., Sevecka M., Tan G., Gerami-Moayed N., Werner S.L., Kohli N., Burenkova O., Sloss C.M., King A.M., et al. Enhanced targeting of the EGFR network with MM-151, an oligoclonal anti-EGFR antibody therapeutic. Mol Cancer Ther 2015, 14:1625-1636.
24. Dienstmann R., Patnaik A., Garcia-Carbonero R., Cervantes A., Benavent M., Rosello S., Tops B.B.J., van der Post R.S., Argiles G., Skartved N.J.O., et al. Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov 2015, 5:598-609.
25. Pedersen M.W., Jacobsen H.J., Koefoed K., Hey A., Pyke C., Haurum J.S., Kragh M. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010, 70:588-597.
26. Fox J.L. Anti-infective monoclonals step in where antimicrobials fail. Nat Biotechnol 2013, 31:952-954.
27. Kang S.-J., Kim D.-H., Mishig-Ochir T., Lee B.-J. Antimicrobial peptides: their physicochemical properties and therapeutic application. Arch Pharm Res 2012, 35:409-413.
28. Saylor C., Dadachova E., Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009, 27(Suppl 6):G38-G46.
29. Berry J.D., Gaudet R.G. Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. New Biotechnol 2011, 28:489-501.
30. Dadachova E., Casadevall A. Radiolabeled antibodies for therapy of infectious diseases. Microbiol Spectr 2014, 2:1-9.
31. Lowy I., Molrine D.C., Leav B.A., Blair B.M., Baxter R., Gerding D.N., Nichol G., Thomas W.D., Leney M., Sloan S., et al. Treatment with monoclonal antibodies against clostridium difficile toxins. N Engl J Med 2010, 362:197-205.
32. Marozsan A.J., Ma D., Nagashima K.A., Kennedy B.J., Kang Y., Arrigale R.R., Donovan G.P., Magargal W.W., Maddon P.J., Olson W.C. Protection against clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis 2012, 206:706-713.
33. Rouha H., Badarau A., Visram Z.C., Battles M.B., Prinz B., Magyarics Z., Nagy G., Mirkina I., Stulik L., Zerbs M., et al. Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs 2015, 7:243-254.
34. Bitzan M., Poole R., Mehran M., Sicard E., Brockus C., Thuning-Roberson C., Rivière M. Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother 2009, 53:3081-3087.
35. Lu Q., Eggimann P., Luyt C.-E., Wolff M., Tamm M., François B., Mercier E., Garbino J., Laterre P.-F., Koch H., et al. Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes. Crit Care 2014, 18:R17.
36. Que Y.-A., Lazar H., Wolff M., François B., Laterre P.-F., Mercier E., Garbino J., Pagani J.-L., Revelly J.-P., Mus E., et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis 2014, 33:1861-1867.
37. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., Vachieri S.G., Pinna D., Minola A., Vanzetta F., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333:850-856.
38. Nakamura G., Chai N., Park S., Chiang N., Lin Z., Chiu H., Fong R., Yan D., Kim J., Zhang J., et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 2013, 14:93-103.
39. Corti D., Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013, 31:705-742.
40. de Kruif J., Bakker A.B.H., Marissen W.E., Kramer R.A., Throsby M., Rupprecht C.E., Goudsmit J. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 2007, 58:359-368.
41. Bakker A.B.H., Python C., Kissling C.J., Pandya P., Marissen W.E., Brink M.F., Lagerwerf F., Worst S., van Corven E., Kostense S., et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008, 26:5922-5927.
42. Galun E., Terrault N.a., Eren R., Zauberman A., Nussbaum O., Terkieltaub D., Zohar M., Buchnik R., Ackerman Z., Safadi R., et al. Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J Hepatol 2007, 46:37-44.
43. Pascal K.E., Coleman C.M., Mujica A.O., Kamat V., Badithe A., Fairhurst J., Hunt C., Strein J., Berrebi A., Sisk J.M., et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci 2015, 112:8738-8743.
44. Nayak S.U., Griffiss J.M., McKenzie R., Fuchs E.J., Jurao R.A., An A.T., Ahene A., Tomic M., Hendrix C.W., Zenilman J.M. Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A. Antimicrob Agents Chemother 2014, 58:5047-5053.
45. Cheng L.W., Stanker L.H., Henderson T.D., Lou J., Marks J.D. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 2009, 77:4305-4313.
46. Nowakowski A., Wang C., Powers D.B., Amersdorfer P., Smith T.J., Montgomery V.A., Sheridan R., Blake R., Smith L.A., Marks J.D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci 2002, 99:11346-11350.
47. Nguyen A.W., Wagner E.K., Laber J.R., Goodfield L.L., Smallridge W.E., Harvill E.T., Papin J.F., Wolf R.F., Padlan E.A., Bristol A., et al. A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough. Sci Transl Med 2015, 7. 316ra195.
48. Cohen J. New reports highlight long-term risks from Ebola infection, limits of ZMapp [Internet]. Science 2016, 10.1126/science.aaf4100.
49. Qiu X., Wong G., Audet J., Bello A., Fernando L., Alimonti J.B., Fausther-Bovendo H., Wei H., Aviles J., Hiatt E., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014, 514:47-53.
50. Moore G.L., Chu S., Pong E., Wickramarachchi D., Endo N.A., Chan E.W., Phung S., Chen H., Leung I., Bonzon C., et al. Accelerated clearance of IgE in chimpanzees is mediated by XmAb7195, An Fc-engineered antibody with enhanced affinity for inhibitory receptor FcγRIIb. Am J Respir Crit Care Med 2014, 189:A4261.
51. Piccoli L., Campo I., Fregni C.S., Rodriguez B.M.F., Minola A., Sallusto F., Luisetti M., Corti D., Lanzavecchia A. Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat Commun 2015, 6:7375.
52. Lantto J., Haahr Hansen M., Rasmussen S.K., Steinaa L., Poulsen T.R., Duggan J., Dennis M., Naylor I., Easterbrook L., Bregenholt S., et al. Capturing the natural diversity of the human antibody response against vaccinia virus. J Virol 2011, 85:1820-1833.
53. Zaitseva M., Kapnick S.M., Meseda C.A., Shotwell E., King L.R., Manischewitz J., Scott J., Kodihalli S., Merchlinsky M., Nielsen H., et al. Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs. J Virol 2011, 85:9147-9158.
54. Lugovskoy A.A., Geddie M.L. Antibody-like molecules designed for superior targeting and pharmacokinetics. Biobetters 2015, 203-220. Springer, New York. A. Rosenberg, B. Demeule (Eds.).
55. Hendriks B.S., Klinz S.G., Reynolds J.G., Espelin C.W., Gaddy D.F., Wickham T.J. Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect. Mol Cancer Ther 2013, 12:1816-1828.
56. D'Souza J.W., Robinson M.K. Oligoclonal antibodies to target the ErbB family. Expert Opin Biol Ther 2015, 15:1015-1021.
57. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
58. Lopez J., Harris S., Roda D., Yap T.A. Precision medicine for molecularly targeted agents and immunotherapies in early-phase clinical trials. Transl Oncogenomics 2015, 7:1-11.
59. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
60. Pleasance E.D., Cheetham R.K., Stephens P.J., McBride D.J., Humphray S.J., Greenman C.D., Varela I., Lin M.-L., Ordóñez G.R., Bignell G.R., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
61. Hoadley K.A., Yau C., Wolf D.M., Cherniack A.D., Tamborero D., Ng S., Leiserson M.D.M., Niu B., McLellan M.D., Uzunangelov V., et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014, 158:929-944.
62. Schwitalla S. Tumor cell plasticity: the challenge to catch a moving target. J Gastroenterol 2014, 49:618-627.
63. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012, 72:4875-4882.
64. Easwaran H., Tsai H.-C., Baylin S.B. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014, 54:716-727.
65. Sidow A., Spies N. Concepts in solid tumor evolution. Trends Genet 2015, 31:208-214.
66. de Bruin E.C., Taylor T.B., Swanton C. Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. Genome Med 2013, 5:101.
67. Cassidy J.W., Caldas C., Bruna A. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res 2015, 75:2963-2968.
68. Alic L., Niessen W.J., Veenland J.F. Quantification of heterogeneity as a biomarker in tumor imaging: A Systematic Review. PLoS One 2014, 9:e110300.
69. Jamal-Hanjani M., Quezada S.A., Larkin J., Swanton C. Translational implications of tumor heterogeneity. Clin Cancer Res 2015, 21:1258-1266.
70. Kim J., Tanner K. Recapitulating the tumor ecosystem along the metastatic cascade using 3D culture models. Front Oncol 2015, 5:170.
71. Crowley E., Di Nicolantonio F., Loupakis F., Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013, 10:472-484.
72. Diaz L.a., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014, 32:579-586.
73. Esposito A., Criscitiello C., Locatelli M., Milano M., Curigliano G. Liquid biopsies for solid tumors: understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. Pharmacol Ther 2016, 157:120-124.
74. Turajlic S., Swanton C. Gastrointestinal cancer: tracking tumour evolution through liquid biopsy. Nat Rev Clin Oncol 2015, 12:565-566.
75. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., Bartlett B.R., Wang H., Luber B., Alani R.M., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014, 6. 224ra24.
76. Tebbutt N., Pedersen M.W., Johns T.G. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 2013, 13:663-673.
77. Ben-Kasus T., Schechter B., Lavi S., Yarden Y., Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A 2009, 106:3294-3299.
78. Pedersen M.W., Jacobsen H.J., Koefoed K., Dahlman A., Kjaer I., Poulsen T.T., Meijer P.-J., Nielsen L.S., Horak I.D., Lantto J., et al. Targeting three distinct HER2 domains with a recombinant antibody mixture overcomes trastuzumab resistance. Mol Cancer Ther 2015, 14:669-680.
79. Modjtahedi H., Eccles S.a., Box G., Styles J., Dean C.J. Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor. Cell Biophys 1993, 22:129-146.
80. Bardelli A., Jänne P.a. The road to resistance: EGFR mutation and cetuximab. Nat Med 2012, 18:199-200.
81. Mukohara T. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci 2011, 102:1-8.
82. Arena S., Bellosillo B., Siravegna G., Martinez A., Canadas I., Lazzari L., Ferruz N., Russo M., Misale S., Gonzalez I., et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 2015, 21:2157-2166.
83. Koefoed K., Steinaa L., Søderberg J.N., Kjær I., Jacobsen H.J., Meijer P.-J., Haurum J.S., Jensen A., Kragh M., Andersen P.S., et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011, 3:584-595.
84. Spangler J.B., Neil J.R., Abramovitch S., Yarden Y., White F.M., Lauffenburger D.A., Wittrup K.D. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci 2010, 107:13252-13257.
85. Arena S., Siravegna G., Mussolin B., Kearns J.D., Wolf B.B., Misale S., Lazzari L., Bertotti A., Trusolino L., Adjei A.A., et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med 2016, 8. 324ra14.
86. Iida M., Brand T.M., Starr M.M., Huppert E.J., Luthar N., Bahrar H., Coan J.P., Pearson H.E., Salgia R., Wheeler D.L. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer 2014, 13:242.
87. Huang S.-M., Li C., Armstrong E.a., Peet C.R., Saker J., Amler L.C., Sliwkowski M.X., Harari P.M. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2013, 73:824-833.
88. Jacobsen H.J., Poulsen T.T., Dahlman A., Kjaer I., Koefoed K., Sen J.W., Weilguny D., Bjerregaard B., Andersen C.R., Horak I.D., et al. Pan-HER, an antibody mixture simultaneously targeting EGFR, HER2, and HER3, effectively overcomes tumor heterogeneity and plasticity. Clin Cancer Res 2015, 21:4110-4122.
89. von Behring E., Kitasato S. The mechanism of diphtheria immunity and tetanus immunity in animals. 1890. Mol Immunol 1991, 28:1317. 1319-20.
90. Matsushita H., Sano A., Wu H., Wang Z., Jiao J.-A., Kasinathan P., Sullivan E.J., Kuroiwa Y. Species-specific chromosome engineering greatly improves fully human polyclonal antibody production profile in cattle. PLoS One 2015, 10:e0130699.
91. Kuroiwa Y., Kasinathan P., Choi Y.J., Naeem R., Tomizuka K., Sullivan E.J., Knott J.G., Duteau A., Goldsby R.A., Osborne B.A., et al. Cloned transchromosomic calves producing human immunoglobulin. Nat Biotechnol 2002, 20:889-894.
92. Lalloo D.G., Theakston R.D.G. Snake antivenoms. Clin Toxicol 2003, 41:277-290. 317-27.
93. Hsu J.L., Safdar N. Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases. Infect Dis Clin North Am 2011, 25:773-788.
94. Casadevall A., Dadachova E., Pirofski L. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004, 2:695-703.
95. Sharon J., Liebman M.A., Williams B.R. Recombinant polyclonal antibodies for cancer therapy. J Cell Biochem 2005, 96:305-313.
96. Lazar G.A., Desjarlais J.R. Engineering the antibody Fc region for optimal effector function. Therapeutic Monoclonal Antibodies: From Bench to Clinic 2009, 349-370. John Wiley & Sons, Inc. Z. An (Ed.).
97. Almagro J.C., Strohl W.R. Antibody engineering: humanization, affinity maturation, and selection techniques. Therapeutic Monoclonal Antibodies: From Bench to Clinic 2009, 309-334. John Wiley & Sons, Inc. Z. An (Ed.).
98. Spiess C., Zhai Q., Carter P.J. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015, 67:95-106.
99. Nuñez-Prado N., Compte M., Harwood S., Álvarez-Méndez A., Lykkemark S., Sanz L., Álvarez-Vallina L. The coming of age of engineered multivalent antibodies. Drug Discov Today 2015, 20:588-594.
100. DiGiandomenico A., Keller A.E., Gao C., Rainey G.J., Warrener P., Camara M.M., Bonnell J., Fleming R., Bezabeh B., Dimasi N., et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 2014, 6. 262ra155-262ra155.
101. Harms B.D., Kearns J.D., Iadevaia S., Lugovskoy A.A. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods 2014, 65:95-104.
102. Daniel-Ribeiro Combination vaccines: development, clinical research and approval. Mem Inst Oswaldo Cruz 2000, 95:279.
103. European Medicines Agency Guideline on clinical development of fixed combination medicinal products 2015, EMA/CHMP/281825.
104. Guidance for Industry: Codevelopment of Two or More New Investigational Drugs for Use in Combination 2013, U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research.
105. Proposed Rules for Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph. Fed Regist 2015, 80:79776-79795.
106. Lauritsen K., Nguyen T. Combination Products Regulation at the FDA. Clin Pharmacol Ther 2009, 85:468-470.
107. Robak T., Windyga J., Trelinski J., von Depka Prondzinski M., Giagounidis A., Doyen C., Janssens A., Alvarez-Roman M.T., Jarque I., Loscertales J., et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012, 120:3670-3676.
108. Wang F., Chen L., Connors N., Mach H. Antibody expression in mammalian cells. Therapeutic monoclonal antibodies: from bench to clinic 2009, 555-572. John Wiley & Sons, Inc. Z. An (Ed.).
109. Joos B., Trkola A., Kuster H., Aceto L., Fischer M., Stiegler G., Armbruster C., Vcelar B., Katinger H., Gunthard H.F. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus Type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother 2006, 50:1773-1779.
110. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., Manrique A., Huber M., Rehr M., Oxenius A., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005, 11:615-622.
111. de Kruif J., Kramer A., Nijhuis R., van der Zande V., den Blanken R., Clements C., Visser T., Keehnen R., den Hartog M., Throsby M., et al. Generation of stable cell clones expressing mixtures of human antibodies. Biotechnol Bioeng 2010, 106:741-750.
112. Nielsen L.S., Baer A., Müller C., Gregersen K., Mønster N.T., Rasmussen S.K., Weilguny D., Tolstrup A.B. Single-batch production of recombinant human polyclonal antibodies. Mol Biotechnol 2010, 45:257-266.
113. Babcock G.J., Broering T.J., Hernandez H.J., Mandell R.B., Donahue K., Boatright N., Stack A.M., Lowy I., Graziano R., Molrine D., et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006, 74:6339-6347.
114. Lyras D., O'Connor J.R., Howarth P.M., Sambol S.P., Carter G.P., Phumoonna T., Poon R., Adams V., Vedantam G., Johnson S., et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009, 458:1176-1179.
115. Merrimack Pharmaceuticals: Phase 1 Combination Study of MM-151 and MM-121. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 [cited 2016 Feb 22]. Available from: https://clinicaltrials.gov/show/NCT02538627 NLM Identifier:. ctgov:NCT02538627.